<DOC>
	<DOCNO>NCT00190502</DOCNO>
	<brief_summary>The primary objective study : - To compare effect ATG treatment together intensified insulin therapy ( Group 1 ) fast glucagon-stimulated C-peptide production intensify insulin therapy ( Group 2 ) type 1 diabetes mellitus recent onset Secondary objective : - To compare insulin dos two group 6 , 12 , 18 , 24 month diabetes onset - To compare course specific humoral marker autoimmunity group - To evaluate significance vitro test specific T-cell activation autoantigen long-term follow-up type 1 diabetes - To assess safety ATG treatment type 1 diabetes</brief_summary>
	<brief_title>Polyclonal Anti-T-Lymphocyte Globulin ( ATG ) Type 1 Diabetes</brief_title>
	<detailed_description>This randomize , control , single-blind parallel group study . After admission hospital , initial physical laboratory examination perform . Laboratory test medical treatment relate experimental protocol ( except immunosuppressive drug ) perform clinically need . Patients fulfill inclusion criterion give inform consent participate study randomize treat either course ATG-Fresenius together intensify insulin therapy ( Group 1 ) intensify insulin therapy ( Group 2 ) . For study purpose , clinical laboratory status patient assess 14 occasion ( screen , visit 1 – visit 14 ) . Thereafter , extend follow-up study plan evaluation every 6 month . Patients refer research institution cooperate general practitioner diabetes specialist , preferably initiation insulin therapy . After diabetes confirmation ( accord WHO criterion ) initial clinical biochemical examination ( typical patient recent onset diabetes ) purpose , potential risk benefit design study explain . Subjects willing participate study ask give write informed consent . All patient actively educate diabetes management intensified insulin therapy ( 3 – 4 daily injection human insulin , glucose self-monitoring ) initiate accord individual need . In subject randomize Group 1 , 4 dos ATG Fresenius ( first dose 9 mg/kg body weight , 3 consecutive dos 3 mg/kg ) administer intravenously 4 hour . Subjects Group 2 treat saline infusion ( 500 ml ) day . 1 hour first ATG administration , cutaneous tolerance test ( 0.2 ml final solution ) perform . Approximately 10 day admission patient dismiss . Besides schedule ambulant visit , subject followed-up clinically need . In Paediatric patient ( age 15-18 year ) , recommendation paediatric endocrinologist concern diabetes management respect . After completion study patient ’ diabetes specialist acquainted course treatment far patient treat accord individual need . They see regularly per year Department Diabetes IKEM next 3 year . Discontinuation study : Participation study may time stop accord patient ’ . Should require medical status patient , study may interrupt base investigator ’ decision period ATG administration . Study population : Twenty four patient type 1 diabetes mellitus recent onset follow Institute Clinical Experimental Medicine Prague . Inclusion criterion : - Type 1 diabetes mellitus know duration 6 week - Men woman 15 – 35 year old , body mass index 32 kg/m2 , exclusion gravidity woman - Insulin dose 40 IU per day longer 1 month - C-peptide level ≥ 0.3 pmol/ml 4 min . follow iv . administration 1 ml glucagon - No previous immunosuppressive therapy , concurrent severe infection , granulocyte count ≥ 2 x 10^9/l , platelet count ≥ 120 x 10^9/l</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Type 1 diabetes Body mass index 32 kg/m2 Exclusion gravidity woman Known diagnosis diabetes less 6 week Insulin dose 40 IU per day longer 1 month Positive least one autoantibody ( GAD , IA2 , ICA ) Cpeptide level ≥ 0.3 pmol/ml 4 min . follow intravenous ( IV ) administration 1 ml glucagon No concurrent severe infection Granulocyte count ≥ 2 x 10^9/l Platelet count ≥ 120 x 10^9/l Other nondiabetes relate autoimmune disease Previous immunosuppressive therapy Any clinical impairment preclude immunosuppressive therapy Leucopenia thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Immune intervention</keyword>
	<keyword>Polyclonal antibody</keyword>
	<keyword>Type 1 diabetes recent onset</keyword>
	<keyword>C-peptide level 0.3 pmol/l high</keyword>
	<keyword>Positivity least one marker autoimmunity ( diabetes )</keyword>
</DOC>